Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KNK 002

Next Previous
Drug Profile

KNK 002

Alternative Names: CSTD 002 NK; CSTD002; K-NK002; mbIL21 ex-vivo expanded donor-derived NK cells

Latest Information Update: 12 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytoSen Therapeutics
  • Developer Kiadis Pharma; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 12 Dec 2022 No development reported - Phase-II for Acute myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral) (Sanofi pipeline; December 2022)
  • 12 Dec 2022 No development reported - Phase-II for Chronic myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral) (Sanofi pipeline; December 2022)
  • 12 Dec 2022 No development reported - Phase-II for Myelodysplastic syndromes (Second-line therapy or greater) in USA (Parenteral) (Sanofi pipeline; December 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top